Pegcetacoplan intravitreal injections continued to reduce geographic atrophy lesion growth in patients with age-related macular degeneration at 18 months, according to two phase 3 studies.
The positive long-term results of the DERBY and OAKS studies show that the intravitreal drug has the potential to slow disease progression and preserve a patient’s vision for longer, Apellis Pharmaceuticals announced in a press release.
“Geographic atrophy is a tremendously devastating disease that severely impacts vision and leads to, essentially, loss of vision, legal blindness and loss of